Working… Menu

Relationship Between Circulating Tumor Stem Cells and the Clinical Pathology

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02727673
Recruitment Status : Completed
First Posted : April 4, 2016
Last Update Posted : April 4, 2016
Information provided by (Responsible Party):
ShenFeng, Eastern Hepatobiliary Surgery Hospital

Brief Summary:
The aim of this study is to establish a platform of detecting and sorting circulating tumor stem cells from peripheral blood in HCC patients; to investigate the relationship between circulating tumor stem cells and their effects on postoperative recurrence and metastasis, in order to provide a new therapeutic target for hepatocellular carcinoma treatment.

Condition or disease
Cancer Stem Cells Postoperative Recurrence and Metastasis Hepatocellular Carcinoma

Layout table for study information
Study Type : Observational
Actual Enrollment : 1000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective Randomized Trial on the Relationship Between Circulating Tumor Stem Cells and the Clinical Pathology
Study Start Date : December 2012
Actual Primary Completion Date : August 2014
Actual Study Completion Date : December 2014

healthy volunteers
matched group
hepatitis cirrhosis
negative group
hepatocellular carcinoma
patients with primary HCC

Primary Outcome Measures :
  1. the overall survival rate of each group [ Time Frame: 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
250 healthy volunteers, 250 patients with hepatitis cirrhosis, 500 patients with HCC;

Inclusion Criteria:

  1. Male or female patients > 18 years and <=70 years of age;
  2. No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung function are basically normal.
  3. Patients who can understand this trial and have signed information consent

Exclusion Criteria:

  1. Reject to attend;
  2. Impossible to come to our hospital for physical examination regularly;
  3. Patients with other diseases which may affect the treatment mentioned

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02727673

Layout table for location information
China, Shanghai
Eastern hepatobilliary surgery hospital
Shanghai, Shanghai, China, 200438
Sponsors and Collaborators
Eastern Hepatobiliary Surgery Hospital

Layout table for additonal information
Responsible Party: ShenFeng, vice president of the Eastern Hepatobiliary Surgery Hospital, Eastern Hepatobiliary Surgery Hospital Identifier: NCT02727673     History of Changes
Other Study ID Numbers: ZD201200102-P1
First Posted: April 4, 2016    Key Record Dates
Last Update Posted: April 4, 2016
Last Verified: March 2016
Keywords provided by ShenFeng, Eastern Hepatobiliary Surgery Hospital:
cancer stem cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Pathologic Processes
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Disease Attributes